The study, which took place over a one-year period, worked to understand if including a pharmacist in the PrEP care process would reduce the barriers around the prescription and its use.The study was led by pharmacists from a university-based HIV clinic, community pharmacy and two community-based clinics.
The pharmacists in the study conducted PrEP visits with potential candidates for the prevention therapy and prescribed emtricitabine-tenofovir disoproxil fumarate. Over the study period, pharmacists tracked retention, patient satisfaction and pharmacist acceptability.
The study authors found that 100 percent of the participants said they would recommend the program. However, the patient retention rate fell to 28 percent by the end of the study period.
None of the patients tested positive for HIV during the study, according to Pharmacy Times.
Pharmacists reported feeling comfortable during the PrEP visits and rarely reported workflow disruption.
Read the full report here.
More articles on pharmacy:
Florida compounding facility recalls all human and animal drugs for lack of sterility
Despite ‘Right-to-try’ law, drugmakers still prefer FDA review, GAO finds
Opioid settlements may mean big tax breaks for Big Pharma
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
